← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 DELISTED CERo Therapeutics CERO	–	–	–	–
102	102 Calidi Biotherapeutics CLDI $2.26M	–	–	–	–
103	103 DELISTED Centogene N.V. Common Shares CNTG	–	–	–	–
104	104 Coya Therapeutics COYA $98.1M	–	–	–	–
105	105 Caribou Biosciences CRBU $49.3M	–	–	–	–
106	106 DELISTED CARGO Therapeutics CRGX	–	–	–	–
107	DBTX 107 DELISTED Decibel Therapeutics, Inc. Common Stock DBTX	–	–	–	–
108	108 DELISTED DermTech, Inc. Common Stock DMTK	–	–	–	–
109	109 Ginkgo Bioworks DNA $776M	–	–	–	–
110	110 Design Therapeutics DSGN $609M	–	–	–	–
111	111 Precision BioSciences DTIL $166M	–	–	–	–
112	112 enGene Therapeutics ENGN $105M	–	–	–	–
113	113 Estrella Immunopharma ESLA $13.8M	–	–	–	–
114	114 FibroBiologics FBLG $6.73M	–	–	–	–
115	115 4D Molecular Therapeutics FDMT $674M	–	–	–	–
116	FRLN 116 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
117	117 DELISTED Generation Bio GBIO	–	–	–	–
118	118 CytoMed Therapeutics GDTC $10.3M	–	–	–	–
119	119 Guardant Health GH $21.9B	–	–	–	–
120	GMDA 120 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
121	121 Corgi Genomics & Precision Medicine ETF GNMX $1.64M	–	–	–	–
122	122 Global X Genomics & Biotechnology ETF GNOM $97.9M	–	–	–	–
123	123 Genprex GNPX $1.91M	–	–	–	–
124	124 Genenta Science GNTA $31.8M	–	–	–	–
125	125 GRAIL Inc GRAL $6.24B	–	–	–	–